Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So whats driving the price action today? - market way down again!
J.L. relax, just joking around - I think Dr. Nissen deserves a little snub.
Very important note to be made. This is a preventative medicine EPA/AA rations need to be monitored from early teens and on. Hell they are trying to put teens on Statins. which is a bit crazy if you ask me.
Your the man! Excellent job.
Stick with your true calling, it works for you. love the scale approach and building blocks.
Now if I may, for a laugh - you place Dr. Deepak Bhaat's head on the left scale and Dr. Nissen's head on the Right scale.
Thanks,
B.C.
I really think his true calling in life is Graphic Artist!
Icosapent Ethyl (EPA) Give it a scientific sound in addition to just EPA. The photo looks like pile of regular fish oil - Vascepa looks clearer, nearly colorless.
Good find Zum, makes me think partnership on the horizon.
There was proof the drug (EPA) worked to reduce Cardio Events, they just refused to believe it. Thus made a even bigger mistake by not approving the drug and many lost lives.
This is serious stuff, but the Market always has a knee jerk reaction over any little thing. Day before yesterday it was the inverted yield curve which set of the AI machines to start a massive selloff. They need to pull the plug on these High Frequency Trading Schemes, very dangerous.
LMAO - :>)
I would but I used up my 5 Ignor's.
So in another words, you have no idea what the price action will be in the comings months!
Ok FFS what is the price of AMRN end of next week, and follow up with the end of the month, finally end of 2nd quarter 2019.
Mod's sticky his answer to the top of the board!
Have you been playing with that fairy dust again. I'm sure Santa will have something to say about that.
Compared to bypass surgery or ER and ICU extended stays. Yep I'm sure your right.
This is the most foolish arrogant thing you could possibly say. Your chart could never predict future market/sales numbers or PPS. You have shown how clueless you really are.
I don't have a problem with exposure or what you guys are trying to do. I'm just frustrated with the careless internet reporting and negative press. This is a great drug so we have need to have a spoke person rather then J.T., who can respond to any negative press and provide a clear and concise feed back for the great Reduce-it results. The focus should turn from Triglycerides to EPA/AA ratios as soon as possible and I hope you plane on making P.C.'s aware of the EPA/AA ratio test that are available.
J.L. I think you have an apples and oranges situation. This is a prescription drug that can not be sold to anyone with cash in hand.
You are putting a lot of faith in your fellow doctors to write scripts and not to mention the insurance carriers to catch up fast with Tier 2 coverage. Even if docs start writing scripts the insurance carriers may fall behind in coverage. I believe it may be a slow road until FDA hands down approval 6-10 months after Reduce-It sNDA is filed. Hopefully Amarin can get the nod from the FDA to start a marketing Reduce-It results to doctors. Seems to be a lot of foolish resistance because of bad press, no thanks to Dr. Steven Nissen bad mouthing Reduce-It trial. Remember all he has to to is instill doubt and not prove anything.
The company needs to release a paper that mineral oil had no effect and release it to combat the negative press articles and a rebuttal to Dr. Steven Nissen's claims regarding MO. He certainly stirred the pot.
Can’t do it now taking off on the sea plane
That’s way it would have been an excellent placebo. For the very little benefit at 4 grams compared to 4 grams of Vascepa there would have been no argument about the active arms risk reduction.
I believe olive oil has been used as a placebo. Another fishy article based on MO released today. Probably another anonymous author.
More of the endless MO debacle. They
should have made plans to substitute the MO with extra virgin olive oil years ago, when this ugly monster rose its head.
Extra Virgin Olive Oil very light color and tasteless.
Only on the buyout banter! Not thrilled about GIA, but so be it.
This was probably pre-scheduled, not arranged very long ago. The rules can be a bit vague. As long as they avoid what looks like insider trades. There is a note not to sell before Nov 12. So they must have know the results of reduce-It would become public knowledge on the 12th.
3. Date of Earliest Transaction
(Month/Day/Year)
11/12/2018
My gut feeling J.T. would not have sold just over 600,000 shares, if he thought the price would move up into the higher price regions, in a short time frame. This sale he initiated also gives me a sense, there is little chance the company will be sold. Why sell a large portion of holdings knowing you may more then double your money.
Maybe his name is Dr. Steven Nissen. :>)
I would start with an EPA/AA ratio test, as you know if this is way off. The 500mg worth of fish oil they are taking is in effective.
AA/EPA RATIO PLASMA
Test Code
17864
CPT Code(s)
82491
Preferred Specimen(s)
3 ML PLASMA COLLECTED IN EDTA (LAVENDER-TOP) TUBE.
INSTRUCTIONS:
PATIENT MUST BE FASTING FOR 8 TO 12 HOURS FOR THIS TEST.
PATIENT MAY HAVE WATER. IT IS NOT NECESSAY TO DISCONTINUE
NUTRITIONAL SUPPLEMENTS OR ORAL HORMONES PRIOR TO THIS TEST.
ABNORMALITIES THAT MAY BE FOUND WILL REVEAL SPECIAL
NEEDS THAT HAVE NOT BEEN MET BY RECENT DIETARY AND
SUPPLEMENTAL INTAKE.
Transport Container
PLASTIC SCREW-CAP VIAL
Transport Temperature
FROZEN
Specimen Stability
ROOM TEMPERATURE: NOT STABLE
REFRIGERATED: NOT STABLE
FROZEN: 6 MONTHS
Reject Criteria
THAWED SPECIMENS
Methodology
GAS CHROMATOGRAPHY/MASS SPECTROMETRY (GC/MS)
Performing Laboratory
GENOVA DIAGNOSTICS (METAMETRIX)
3425 CORPORATE WAY
DULUTH GA 30096-2579
Setup Days
MONDAY-THRUSDAY ONLY
Clinical Significance
THIS UNIQUE TEST MEASURES THE RATIO OF ARACHIDONIC ACID
(AA) TO EICOSAPENTAENOIC ACID (EPA) IN PLASMA OR SERUM.
THIS RATIO OF THE PRINCIPLE OMEGA-3 AND OMEGA-6 FATTY
ACIDS IS A MEASURE OF THE BODY'S EICOSANOID BALANCE.
BALANCING THE EICOSANOIDS IN THE BODY IS AN EXCELLENT
WAY FOR MANAGING HEART DISEASE AND OTHER CHRONIC AND
INFLAMMATORY PROCESSES.
Has anyone brought up the question regarding Anchor sNDA to investor relations.
Yes agree there. I had the same problems with UHC and Tier 3. I like BC/BS Tier 2 coverage, but they pulled out of the Virgin Islands/Puerto Rico region. Leaving us the UHC. :>(
I thought it was some old wives tale. I take my morning dose with a fat cup of coffee. :>)
This may give some insight to the EPA dosages and when taken decisions.
This study was designed and sponsored by Amarin Pharma, Inc., Bedminster, NJ, USA. Editorial assistance was provided by Peloton Advantage, LLC, Parsippany, NJ, USA, funded by Amarin Pharma, Inc.
EPA Blood Plasma Dosages and half life
PS haven't had this time to go over this yet.
J.L. could probably come up with some conclusions regarding dosages of EPA.
Will you have to remember PCP's write a lot of Statin scripts, add Vascepa to those numbers and beyond.
Well thanks for the reply - hope to hear back regarding your thoughts. It's an interesting dilemma the FDA created with the Anchor approval/SPA denial. We may see an update regarding Anchor sNDA filing status from the company. I think it would help us get a running start, rather than a crawl, waiting for the new sNDA to move through the process.
By next week this will be a fading memory, like the fake MO fiasco.
Thanks for that 30 minute time slice Clay Trader...whoops. J.L.
3 days seems pretty standard..
Kinda like a couple of weeks ago - over reaction.
Hi OldYeller187,
What are your thoughts regarding the Anchor sNDA filing and should it be revived and approved based a new information provided by Amarin. I believe Anchor Approval would open the doors at least for the Insurance Companies, that have Vascepa on Tier 3 which requires proof of high Triglycerides. Moving to Tier 2 coverage and a larger patient population for the short term. The FDA on good faith could patch things up based on the new findings. Seems this process could be expedited by the FDA.
Not sure what Amarin management is thinking regarding this matter.
Welcome to the Amarin Board.
B.C.
Well.. I said: "Mathew, Research before you insert foot into mouth".
He honestly thought Dr. "EPANOVA" was telling him the truth.
Not off hand. There are many potential possibilities. The weight loss would be a blowout for the stock. As you know most weight loss drugs are dangerous or are mostly ineffective.